Citations (73)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
P. Stute, S. Bertschy, M. Birkhaeuser, J. Bitzer, A. Ging, A. Raggi, S. Steimann & V. Stute. (2022) Swiss consensus on the role of DHEA in the management of genitourinary syndrome of menopause. Climacteric 25:3, pages 246-256.
Read now
Read now
Michelle Holton, Chelsea Thorne & Andrew T. Goldstein. (2020) An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause. Expert Opinion on Pharmacotherapy 21:4, pages 409-415.
Read now
Read now
C. Peixoto, C. G. Carrilho, J. A. Barros, T. T. S. B. Ribeiro, L. M. Silva, A. E. Nardi, A. Cardoso & A. B. Veras. (2017) The effects of dehydroepiandrosterone on sexual function: a systematic review. Climacteric 20:2, pages 129-137.
Read now
Read now
Marlene Montesino, Fernand Labrie, David F. Archer, Jaâfar Zerhouni, Isabelle Côté, Lyne Lavoie, Adam Beauregard, Céline Martel, Mario Vaillancourt, Erick Moyneur & John Balser. (2016) Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecological Endocrinology 32:3, pages 240-245.
Read now
Read now
F. Labrie, M. Montesino, D. F. Archer, L. Lavoie, A. Beauregard, I. Côté, C. Martel, M. Vaillancourt, J. Balser & E. Moyneur. (2015) Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric 18:6, pages 817-825.
Read now
Read now
Santiago Palacios & Andrea Mejias. (2015) An update on drugs for the treatment of menopausal symptoms. Expert Opinion on Pharmacotherapy 16:16, pages 2437-2447.
Read now
Read now
S. Palacios, A. Mejía & J. L. Neyro. (2015) Treatment of the genitourinary syndrome of menopause. Climacteric 18:sup1, pages 23-29.
Read now
Read now
C. Bouchard, F. Labrie, D. F. Archer, D. J. Portman, W. Koltun, É. Elfassi, D. A. Grainger, N. Ayotte, T. A. Cooper, M. Martens, A. S. Waldbaum, C. Labrie, I. Côté, L. Lavoie, C. Martel & J. Balser. (2015) Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric 18:4, pages 590-607.
Read now
Read now
Rossella E Nappi & Laura Cucinella. (2015) Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opinion on Pharmacotherapy 16:6, pages 875-887.
Read now
Read now
R. E. Nappi, N. Panay, N. Bruyniks, C. Castelo-Branco, T. J. De Villiers & J. A. Simon. (2015) The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 18:2, pages 233-240.
Read now
Read now
Zoe R Belkin, Jill M Krapf & Andrew T Goldstein. (2015) Drugs in early clinical development for the treatment of female sexual dysfunction. Expert Opinion on Investigational Drugs 24:2, pages 159-167.
Read now
Read now
Jill M Krapf, Zoe R Belkin & Andrew T Goldstein. (2013) Advances in the treatment of vulvovaginal atrophy. Expert Review of Obstetrics & Gynecology 8:5, pages 457-465.
Read now
Read now
T. J. de Villiers, A. Pines, N. Panay, M. Gambacciani, D. F. Archer, R. J. Baber, S. R. Davis, A. A. Gompel, V. W. Henderson, R. Langer, R. A. Lobo, G. Plu-Bureau & D. W. Sturdee. (2013) Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16:3, pages 316-337.
Read now
Read now
Janet A Chollet. (2011) Update on alternative therapies for vulvovaginal atrophy. Patient Preference and Adherence 5, pages 533-536.
Read now
Read now
D. W. Sturdee & A. Pines. (2011) Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 14:3, pages 302-320.
Read now
Read now
Articles from other publishers (58)
Elizabeth A. Casiano Evans, Deslyn T. G. Hobson, Sarit O. Aschkenazi, Alexandriah N. Alas, Sunil Balgobin, Ethan M. Balk, Alexis A. Dieter, Gregory Kanter, Francisco J. Orejuela, Tatiana V. D. Sanses & David D. Rahn. (2023) Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause. Obstetrics & Gynecology 142:3, pages 555-570.
Crossref
Crossref
Susan R. Davis, JoAnn Pinkerton, Nanette Santoro & Tommaso Simoncini. (2023) Menopause—Biology, consequences, supportive care, and therapeutic options. Cell 186:19, pages 4038-4058.
Crossref
Crossref
James A. Simon, Alex Ferenczy, Denise Black, Alex Castonguay, Catherine Royer, Rafik Marouf & Catherine Beauchemin. (2023) Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis. Menopause 30:8, pages 855-866.
Crossref
Crossref
Łukasz Nowakowski, Krzysztof Gałczyński, Michał Dybowski, Rafał Typek, Andrzej Dawidowicz, Paweł Miotła, Piotr Olcha & Tomasz Rechberger. (2023) Effects of topical dehydroepiandrosterone therapy in women after pelvic organ prolapse surgery. Menopause 30:6, pages 629-634.
Crossref
Crossref
S. Vandamme, N. Willers & S. Han. (2022) Lokaal gebruik van dehydro-epiandrosteron voor de behandeling van vaginale atrofie na borstkanker. Tijdschrift voor Geneeskunde.
Crossref
Crossref
Ayane Cristine Alves Sarmento, Ana Paula Ferreira Costa, Juliana Lírio, José Eleutério Jr, Pedro Vieira Baptista & Ana Katherine Gonçalves. (2022) Efficacy of Hormonal and Nonhormonal Approaches to Vaginal Atrophy and Sexual Dysfunctions in Postmenopausal Women: A Systematic Review. Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics 44:10, pages 986-994.
Crossref
Crossref
Susan R. Davis & Rodney J. Baber. (2022) Treating menopause — MHT and beyond. Nature Reviews Endocrinology 18:8, pages 490-502.
Crossref
Crossref
Petra Stute. (2022) Die Rolle von vaginalem DHEA bei der Behandlung des genitourinären Syndroms der MenopauseLe rôle de la DHEA vaginale dans le traitement du syndrome génito-urinaire de la ménopause. Journal für Gynäkologische Endokrinologie/Schweiz 25:2, pages 87-100.
Crossref
Crossref
Roger A. Lobo. 2022. Comprehensive Gynecology. Comprehensive Gynecology
255
288.e9
.
Monica Michelle Christmas, Bonnie Song, Robin J. Bell, Stamatina Iliodromiti, Caroline Mitchell & Martha Hickey. (2020) Variation in outcome reporting and measurement tools in clinical trials of treatments for genitourinary symptoms in peri- and postmenopausal women: a systematic review. Menopause 27:9, pages 1070-1080.
Crossref
Crossref
Suneela VeguntaJuliana M. KlingEkta Kapoor. (2020) Androgen Therapy in Women. Journal of Women's Health 29:1, pages 57-64.
Crossref
Crossref
. (2019) ▼Prasterone for vulvar and vaginal atrophy. Drug and Therapeutics Bulletin 57:12, pages 185-188.
Crossref
Crossref
Santiago Palacios, Rossella E. Nappi, Marla Shapiro, Nilson Roberto de Melo, María Celeste Osorio Wender, César Eduardo Fernandes, Dolores Pardini, Rogério Bonassi Machado, Jaime Kulak, Cuauhtémoc Celis-González, Mabel T. Martino, Rita R. Pizzi, Paulina Villaseca, Eduardo Storch, Luis Fernando Danckers & José Alberto Hernández-Bueno. (2019) An individualized approach to the management of vaginal atrophy in Latin America. Menopause 26:8, pages 919-928.
Crossref
Crossref
Young-A Heo. (2019) Prasterone: A Review in Vulvovaginal Atrophy. Drugs & Aging 36:8, pages 781-788.
Crossref
Crossref
Suneela VeguntaJulia FilesJuliana M. Kling. (2019) Newer Name, Newer Treatments: The Genitourinary Syndrome of Menopause. Journal of Women's Health 28:7, pages 897-899.
Crossref
Crossref
Joanie Mercier, Mélanie Morin, Barbara Reichetzer, Marie-Claude Lemieux, Samir Khalifé & Chantale Dumoulin. (2019) Genitourinary syndrome of menopause symptom severity and impact outcome measures: are they reliable and correlated?. Menopause 26:6, pages 659-664.
Crossref
Crossref
No Author. (2019) Chapitre 6 : Agents thérapeutiques d'ordonnance. Journal of Obstetrics and Gynaecology Canada 41, pages S82-S92.
Crossref
Crossref
Rogerio A. Lobo. 2019. Yen and Jaffe's Reproductive Endocrinology. Yen and Jaffe's Reproductive Endocrinology
322
356.e9
.
Fernand Labrie, David F. Archer, William Koltun, Andrée Vachon, Douglas Young, Louise Frenette, David Portman, Marlene Montesino, Isabelle Côté, Julie Parent, Lyne Lavoie, Adam Beauregard BSc, Céline Martel, Mario Vaillancourt, John Balser & Érick Moyneur. (2018) Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 25:11, pages 1339-1353.
Crossref
Crossref
Eleni Pitsouni, Themos Grigoriadis, Athanasios Douskos, Margarita Kyriakidou, Matthew E. Falagas & Stavros Athanasiou. (2018) Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: A systematic review and meta-analysis of randomized controlled trials. European Journal of Obstetrics & Gynecology and Reproductive Biology 229, pages 45-56.
Crossref
Crossref
Jeanne Carter, Shari B. Goldfarb, Yukio Sonoda, Christian J. Nelson, Maura N. Dickler & John P. Mulhall. 2018. The American Cancer Society's Principles of Oncology. The American Cancer Society's Principles of Oncology
359
378
.
Fernand Labrie. 2018. Pre-Menopause, Menopause and Beyond. Pre-Menopause, Menopause and Beyond
269
284
.
Fernand Labrie. 2018. Pre-Menopause, Menopause and Beyond. Pre-Menopause, Menopause and Beyond
3
15
.
Stephanie S. Faubion, Richa Sood & Ekta Kapoor. (2017) Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. Mayo Clinic Proceedings 92:12, pages 1842-1849.
Crossref
Crossref
Fernand Labrie, David F. Archer, Céline Martel, Mario Vaillancourt & Marlene Montesino. (2017) Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause 24:11, pages 1246-1256.
Crossref
Crossref
David F. Archer, Fernand Labrie, Marlene Montesino & Céline Martel. (2017) Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 μg estradiol on symptoms of vulvovaginal atrophy. The Journal of Steroid Biochemistry and Molecular Biology 174, pages 1-8.
Crossref
Crossref
Fernand LabrieCéline MartelGeorges Pelletier. (2017) Is vulvovaginal atrophy due to a lack of both estrogens and androgens?. Menopause 24:4, pages 452-461.
Crossref
Crossref
Fernand Labrie, Céline Martel, Alain Bélanger & Georges Pelletier. (2017) Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology. The Journal of Steroid Biochemistry and Molecular Biology 168, pages 9-18.
Crossref
Crossref
Fernand Labrie & Céline Martel. (2017) A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values. Hormone Molecular Biology and Clinical Investigation 29:2, pages 39-60.
Crossref
Crossref
Waguih William IsHak, Steven Clevenger, Robert N. Pechnick & Thomas Parisi. 2017. The Textbook of Clinical Sexual Medicine. The Textbook of Clinical Sexual Medicine
413
432
.
Susanna D. Mitro, Siobán D. Harlow, John F. Randolph & Barbara D. Reed. (2016) Chronic vulvar pain in a cohort of post-menopausal women: Atrophy or Vulvodynia?. Women's Midlife Health 2:1.
Crossref
Crossref
Natascia Mennini, Giada Casella, Marzia Cirri, Francesca Maestrelli & Paola Mura. (2016) Development of cyclodextrin hydrogels for vaginal delivery of dehydroepiandrosterone. Journal of Pharmacy and Pharmacology 68:6, pages 762-771.
Crossref
Crossref
Céline Martel, Fernand Labrie, David F. Archer, Yuyong Ke, Renaud Gonthier, Jean-Nicolas Simard, Lyne Lavoie, Mario Vaillancourt, Marlene Montesino, John Balser & Érick Moyneur. (2016) Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks. The Journal of Steroid Biochemistry and Molecular Biology 159, pages 142-153.
Crossref
Crossref
Justin Houman, Tom Feng, Karyn S. Eilber & Jennifer T. Anger. (2016) Female Sexual Dysfunction: Is It a Treatable Disease?. Current Urology Reports 17:4.
Crossref
Crossref
Céline Bouchard, Fernand Labrie, Leonard Derogatis, Ginette Girard, Normand Ayotte, John Gallagher, Leonello Cusan, David F. Archer, David Portman, Lyne Lavoie, Adam Beauregard, Isabelle Côté, Céline Martel, Mario Vaillancourt, John Balser, Erick Moyneur & other participating Members of the VVA Prasterone Group. (2016) Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Hormone Molecular Biology and Clinical Investigation 25:3, pages 181-190.
Crossref
Crossref
Fernand Labrie, David F. Archer, William Koltun, Andrée Vachon, Douglas Young, Louise Frenette, David Portman, Marlene Montesino, Isabelle Côté, Julie Parent, Lyne Lavoie, Adam Beauregard, Céline Martel, Mario Vaillancourt, John Balser & Érick Moyneur. (2016) Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 23:3, pages 243-256.
Crossref
Crossref
Susan R. Davis, Roisin Worsley, Karen K. Miller, Sharon J. Parish & Nanette Santoro. (2016) Androgens and Female Sexual Function and Dysfunction—Findings From the Fourth International Consultation of Sexual Medicine. The Journal of Sexual Medicine 13:2, pages 168-178.
Crossref
Crossref
Jill M. Krapf, John E. Buster & Andrew T. Goldstein. 2016. Management of Sexual Dysfunction in Men and Women. Management of Sexual Dysfunction in Men and Women
233
249
.
Fernand Labrie, Leonard Derogatis, David F. Archer, William Koltun, Andrée Vachon, Douglas Young, Louise Frenette, David Portman, Marlene Montesino, Isabelle Côté, Julie Parent, Lyne Lavoie, Adam Beauregard, Céline Martel, Mario Vaillancourt, John Balser & Érick Moyneur. (2015) Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The Journal of Sexual Medicine 12:12, pages 2401-2412.
Crossref
Crossref
L. Guédra, A. Fèvre & O. Graesslin. (2015) Alternativas al tratamiento hormonal sustitutivo de la menopausia. EMC - Ginecología-Obstetricia 51:4, pages 1-12.
Crossref
Crossref
Yuyong Ke, Fernand Labrie, Renaud Gonthier, Jean-Nicolas Simard, Danielle Bergeron, Céline Martel, Mario Vaillancourt, Marlene Montesino, Lyne Lavoie, David F. Archer, John Balser & Erick Moyneur. (2015) Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration. The Journal of Steroid Biochemistry and Molecular Biology 154, pages 186-196.
Crossref
Crossref
David F. Archer, Fernand Labrie, Céline Bouchard, David J. Portman, William Koltun, Leonello Cusan, Claude Labrie, Isabelle Côté, Lyne Lavoie, Céline Martel & John Balser. (2015) Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause 22:9, pages 950-963.
Crossref
Crossref
David F. Archer. (2015) Vaginal atrophy and disease susceptibility. Menopause 22:8, pages 804-805.
Crossref
Crossref
Fernand Labrie, David F. Archer, Céline Bouchard, Ginette Girard, Normand Ayotte, John C. Gallagher, Leonello Cusan, Mira Baron, François Blouin, Arthur S. Waldbaum, William Koltun, David J. Portman, Isabelle Côté, Lyne Lavoie, Adam Beauregard, Claude Labrie, Céline Martel, John Balser & Érick Moyneur. (2015) Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 81:1, pages 46-56.
Crossref
Crossref
Carola S Scheffers, Sarah Armstrong, Astrid EP Cantineau, Cindy Farquhar & Vanessa Jordan. (2015) Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database of Systematic Reviews 2015:1.
Crossref
Crossref
David F. Archer. (2015) Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. The Journal of Steroid Biochemistry and Molecular Biology 145, pages 139-143.
Crossref
Crossref
Margaret Warner & Jan-Ake Gustafsson. (2015) DHEA ? a precursor of ER? ligands. The Journal of Steroid Biochemistry and Molecular Biology 145, pages 245-247.
Crossref
Crossref
M. A. Weber, J. Limpens & J. P. W. R. Roovers. (2014) Assessment of vaginal atrophy: a review. International Urogynecology Journal 26:1, pages 15-28.
Crossref
Crossref
Jill M. Krapf, Zoe Belkin, Frank Dreher & Andrew T. Goldstein. 2015. Skin, Mucosa and Menopause. Skin, Mucosa and Menopause
229
235
.
Jonathan Bertin, Johanne Ouellet, Alain Yves Dury, Georges Pelletier & Fernand Labrie. (2014) Expression of the estrogen receptors and steroidogenic enzymes involved in estradiol formation in the monkey vagina. American Journal of Obstetrics and Gynecology 211:5, pages 499.e1-499.e9.
Crossref
Crossref
Scott Evan Eder. (2014) Ospemifene: A Novel Selective Estrogen Receptor Modulator for Treatment of Dyspareunia. Women's Health 10:5, pages 499-503.
Crossref
Crossref
. (2014) Managing Menopause Chapter 6 Prescription Therapeutic Agents. Journal of Obstetrics and Gynaecology Canada 36:9, pages S42-S50.
Crossref
Crossref
Tatiane Fernandes, Lucia Helena Costa-Paiva & Aarão Mendes Pinto-Neto. (2014) Efficacy of Vaginally Applied Estrogen, Testosterone, or Polyacrylic Acid on Sexual Function in Postmenopausal Women: A Randomized Controlled Trial. The Journal of Sexual Medicine 11:5, pages 1262-1270.
Crossref
Crossref
Christine Bradway & Joseph Boullata. (2014) Pharmacologic therapy for female sexual dysfunction. The Nurse Practitioner 39:1, pages 16-27.
Crossref
Crossref
Rogerio A. Lobo. 2014. Yen & Jaffe's Reproductive Endocrinology. Yen & Jaffe's Reproductive Endocrinology
308
339.e8
.
Stergios K. Doumouchtsis & Eleftheria L. Chrysanthopoulou. (2013) Urogenital consequences in ageing women. Best Practice & Research Clinical Obstetrics & Gynaecology 27:5, pages 699-714.
Crossref
Crossref
James H. Pickar. (2013) Emerging therapies for postmenopausal vaginal atrophy. Maturitas 75:1, pages 3-6.
Crossref
Crossref
Mary Panjari & Susan R. Davis. (2011) Vaginal DHEA to treat menopause related atrophy: A review of the evidence. Maturitas 70:1, pages 22-25.
Crossref
Crossref